Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
- PMID: 22189742
- PMCID: PMC3226612
- DOI: 10.1590/s1807-59322011001200022
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
Abstract
Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.
Conflict of interest statement
No potential conflict of interest was reported.
References
-
- Gournay V. The ductus arteriosus: Physiology, regulation, and functional and congenital anomalies. Arch Cardiovasc Dis. 2010. 10.1016/j.acvd.2010.06.006 - DOI - PubMed
-
- Gittenberger-de Groot AC. Persistent ductus arteriosus: most probably a primary congenital malformation. Br Heart J. 1977;39:610–8. 10.1136/hrt.39.6.610 - DOI - PMC - PubMed
-
- Chuaqui B, Piwonka G, Farrú O. The wall in persistent ductus arteriosus (in German) Virchows Arch A Pathol Anat Histol. 1977;372:315–24. 10.1007/BF00432406 - DOI - PubMed
-
- Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol. 2001;6:49–61. 10.1053/siny.2000.0037 - DOI - PubMed
-
- Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database of Systematic Reviews. 2010;7:CD000174. 10.1002/14651858.CD000174.pub2 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical